. 2019 Jul 30;11(8):1078. doi: 10.3390/cancers11081078

Table 5.

Selective ongoing clinical trials of adaptive-cell therapies in hepatocellular carcinoma.

Targeted Pathways	Agents Evaluated	Clinical Trial Registration Number
Adaptive cell therapy AFP targeted T-cell receptors	Autologous genetically modified AFPᶜ³³²T cells	NCT03132792
Adaptive cell therapy AFP targeted T-cell receptors	Autologous ET1402L1-CART cells	NCT03349255
Glypican-3 antigen	CAR-Glypican3 T cells	NCT03146234 NCT03198546 NCT02715362 NCT03130712 NCT02959151
Glypican-3 antigen	Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (GLYCAR)	NCT02905188
Glypican-3 antigen	CAR-Glypican3 T cells; leukocyte depletion with cyclophosphamide and fludarabine	NCT03084380 * NCT03302403 ^^,*
c-Met/PD-L1	c-Met/PD-L1 CAR-T Cell Injection	NCT03672305 *

AFP: Alfa fetoprotein; CAR-T: Chimeric Antigen Receptor T-cells; c-Met: Tyrosine kinase MET; PD-L1: Programmed Cell Death Ligand 1. ^ Basket trial; * Not recruiting patients yet.